Titan Pharmaceuticals Inc (TTNP) SEC Filing 8-K Material Event for the period ending Thursday, June 20, 2019

SEC Filings

Titan Pharmaceuticals Inc

CIK: 1715611 Ticker: TTNP

View differences made from one to another to evaluate Titan Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Titan Pharmaceuticals Inc.


Assess how Titan Pharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Titan Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: TTNP
CIK: 910267
Form Type: 8-K Corporate News
Accession Number: 0001144204-19-032717
Submitted to the SEC: Thu Jun 27 2019 4:12:03 PM EST
Accepted by the SEC: Thu Jun 27 2019
Period: Thursday, June 20, 2019
Industry: Biological Products No Disgnostic Substances
  1. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: